metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)
versus placebo
	nivolumab alone
	CheckMate 451 (N ; all population), 2019 Annals of Oncology 30 : ii77–ii80, 2019 J Clin Oncol 2021 Mar 8;JCO2002212. NCT02538666	RCT	Extensive stage SCLC (Es-SCLC) - maintenance (M)	nivolumab	placebo	patients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy	280 / 275	some concern	inconclusive	suggested 33 % decrease in progression or deaths (PFS)
	nivolumab plus ipilimumab
	CheckMate 451 (NI ; all population), 2019 Annals of Oncology 30 : ii77–ii80, 2019 NCT02538666	RCT	Extensive stage SCLC (Es-SCLC) - maintenance (M)	nivolumab plus ipilimumab	placebo	patients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy	279 / 275	some concern	inconclusive	inconclusive 8 % decrease in deaths (OS) (PE) suggested 28 % decrease in progression or deaths (PFS)